MOUNTAIN VIEW, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, announced today that Daniel Weiner, Ph.D., Senior Vice President, Software, and Dr. Laurent Claret, Scientific Consultant, will speak to members of the pharmaceutical and biotechnology industries attending the Annual Meeting of the American College of Clinical Pharmacology titled "Transatlantic Strategies in Early Drug Development," to be held at the Dusseldorf Hilton in Dusseldorf, Germany, February 18, 2006, at 2:30 PM local time. The conference is jointly sponsored by the Association for Applied Human Pharmacology, the American College of Clinical Pharmacology and the Heinrich-Heine-Universitat, Dusseldorf.
Drs. Weiner and Claret will present the pre-conference workshop "Hands-On Research in Modeling and Simulation." The workshop agenda also covers "Basic Tools in Modeling and Simulation" and "Special Aspects of Modeling and Simulation in Drug Development." Included will be a demonstration of Pharsight Trial Simulator. Additional information can be found at http://www.agah-web.de/overview.html .
About Trial Simulator
Pharsight Trial Simulator balances ease-of-use with powerful technology (patent-pending) for defining and testing interactive drug models, exploring and communicating study design attributes, and performing statistical and sensitivity analysis through graphical and statistical summaries. Trial Simulator models encapsulate existing scientific knowledge, to help the entire clinical development team communicate and test ideas, and plan relevant, effective trials for every phase of clinical testing. Pharsight Trial Simulator helps to anticipate risks and preview the range of expected results before R&D dollars are committed to further development of a drug, and human subjects are exposed to experimental therapies.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding anticipated performance of Pharsight's products and the expected benefits to customers from the use of such products. Actual results may differ materially from Pharsight's expectations due to a variety of factors, including general market and business conditions, uncertainties involved in pharmaceutical drug development, changes in the demand for Pharsight's products, the failure to develop new services or to keep pace with technological changes, the failure of Pharsight's services to obtain anticipated levels of customer acceptance or to meet customers' expectations, and changes in government regulation of the pharmaceutical industry. Further information on potential factors that could affect actual results is included in Pharsight's Quarterly Report on Form 10- Q, as filed with the Securities and Exchange Commission on November 14, 2005. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
Registered Trademarks and Trademarks
Pharsight(R) is a registered trademark of Pharsight Corporation. Trial Simulator(TM) is a trademark of Pharsight Corporation.
All other brand and product names are trademarks or registered trademarks of their respective holders.
Pharsight CorporationCONTACT: Investors: Douglas Sherk or Jennifer Beugelmans, both+1-415-896-6820, or Media: Steve DiMattia, +1-646-277-8706, all of EVCGroup, for Pharsight Corporation
Web site: http://www.pharsight.com/
